301 followers
Selective Oral MEK1/2 Inhibitor #Pimasertib in Metastatic #Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial https://t.co/YQObDfrcIz https://t.co/D4azjg7PW3
Selective Oral MEK1/2 Inhibitor #Pimasertib in Metastatic #Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial https://t.co/YQObDfrcIz https://t.co/D4azjg7PW3
Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial. https://t.co/V88D5AkJ4v https://t.co/dB6Ze1CRuj
New article: Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial. https://t.co/ipfo1xwkpY #melanoma #oncology https://t.co/fpO1tFLCQv